The Source — the HYDROGENYX Journal
Journal · 09/10 — Ostojic 2014: fibromyalgia −38% pain in 4 weeks
Paul Fournier
The Serbian randomised trial on 22 fibro patients. Pain index −38% vs −7% placebo.
22 patients. 4 weeks. VAS pain index −38% vs −7% placebo.
Ostojic, Stojanovic et al. 2014 (Journal of Lifestyle Medicine) randomised 22 patients diagnosed with fibromyalgia (ACR 2010 criteria) into two groups: HRW (1 L/day, 7 ppm) vs visually identical still water placebo.
Primary outcome: VAS pain index (0-10 scale). Measurements at T0 and T+4 weeks. Secondary outcomes: Fibromyalgia Impact Questionnaire (FIQ), SF-36 quality of life score.
At T+4 weeks: VAS pain −38% (from 7.2 to 4.5) in the HRW group vs −7% (from 7.1 to 6.6) in placebo (p=0.002). FIQ improved by 21% vs 4%. SF-36 vitality +28% vs +6%.
Modest sample size (pilot study — n=22) but very significant p-value and real clinical effect magnitude. The Acar 2019 meta-analysis confirms the direction and magnitude across ~120 patients cumulated.
Study no. 6 in the HYX corpus. Proposed mechanism: H₂ penetrates neuronal membranes, neutralises •OH directly.
“We're not saying H₂ cures fibromyalgia. We're saying 22 patients saw their VAS drop. That's a difference.”
— Paul Fournier, Founder of HYDROGENYX
In numbers
- −38% — VAS pain
- n=22 RCT — Double-blind
- p=0.002 — Highly significant
HYDROGENYX Flask
The hydrogen ritual, ready in 5 minutes.
Up to ~9,000 ppb of dissolved molecular hydrogen (manufacturer's data), verifiable at home with a DPD test. 400 ml, touch screen, wireless charging base included.
60-day money-back guarantee · 5-year cell warranty · 4× Klarna
The HYDROGENYX Flask is a water preparation device, not a medical device. It does not prevent, treat, or cure any disease.
To go further: the science of hydrogen · the comparison · the FAQ
